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Main manuscript 
Hormone levels and Peyronie’s disease: more than 
testosterone deficiency?  
 
 
ABSTRACT 
 
Introduction. A potential relationship between testosterone deficiency (TD) 
and Peyronie’s disease (PD) has been repeatedly suggested. However, other 
hormone levels may influence the pathogenesis of PD, indicating the need for 
a complete hormonal assessment.  
Aims. To evaluate the association of comorbidities and hormonal profile with 
PD, and the relationship of hormone levels with PD’s severity, including penile 
vascular dysfunction.   
Methods. We retrospectively selected 63 consecutive patients and 65 
controls from our Andrology consult. Demographic, clinical, hormonal profiles 
and Penile Duplex Doppler Ultrassound (PDDU) measurements were 
collected. TD was defined as total testosterone (TT) below 350 ng/dL and PD 
patients with TD (Group 1) were compared with those with normal TT levels 
(Group 2). 
Main Outcome Measures. Identification of comorbidities and hormonal 
profile in PD patients compared to a control group, and correlation of 
characteristics of PD with hormone levels and PDDU values.  
Results. There were no significant differences between PD patients and the 
control group with respect to demographic and clinical data, except for age. 
Follicle-stimulating hormone levels (FSH) were significantly higher in cases 
than in controls (5.1mUI/ml vs. 4.2mUI/ml, respectively; P=0.048). Free 
testosterone and bioavailable testosterone were significantly lower in PD 
patients than in controls (8.0ng/dL vs. 9.15ng/dL, P=0.014, and 192.4ng/dL 
vs. 221.1ng/dL, P=0.015, respectively). Patients with PD presented more TD 
than controls, but with no significant difference (56.3% vs. 43.8%, P=0.475). 
Prolactin levels were directly correlated with curvature’s degrees (r=0.375; 
P=0.003) and with the plaque length (r=0.391; P=0.002), and FSH levels were 
positively correlated with the plaque length (r=0.299; P=0.018). Plaque length 
was significantly higher in group 1 than in group 2 (4.1±1.6cm vs. 3.2±1.03cm; 
P=0.048), with no significant difference regarding the plaque width.  
Conclusion. We demonstrated a relationship between hormone levels and 
PD, beyond TD, which might interfere in the pathophysiology of this disease. 
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Introduction  
 
Peyronie’s disease (PD) is a localized fibrotic disorder involving the 
tunica albuginea of the penis. This acquired, benign condition results in penile 
deformities, mainly penile curvature, pain on erection, and, in some men, 
erectile dysfunction (ED). Consequently, PD is often physical and 
psychologically devastating for patients and may negatively impact partner 
relationships [1-4]. 
 PD was thought to be an uncommon disorder. Nevertheless, contemporary 
studies have estimated the prevalence rate of the disease at approximately 
5%, or even higher [1, 4]. 
 Although the etiology and underlying pathophysiology of PD are not 
completely understood, scarring is most likely the end result of trauma, as a 
known or occult event, or repeated microtrauma to the erect penis in 
genetically susceptible men, leading to inflammation, fragmentation of elastic 
fibers and deposition of excessive collagen [1, 2, 5]. However, it is still unclear 
why the peak onset of PD occurs among men in their fifties if trauma is the 
precipitant event, as the frequency of sexual intercourse tends to be greater in 
young men. One possibility is a cumulative effect of repetitive minor injuries to 
the tunica albuginea over time, and a recent study suggests that it may be 
due to relatively low serum testosterone levels in older man [5].   
 Comorbid systemic diseases have been shown to increase the risk for 
developing more severe PD, independent of age [2]. Patients with diabetes 
mellitus (DM) and/or hypercholesterolemia were at a significantly higher risk 
of experiencing severe (> 60°) penile curvature [2, 6-9]. PD is also strongly 
associated with Dupuytren’s contracture [1, 10, 11]. Approximately 20% of PD 
men will demonstrate this autosomal dominant fibrotic condition [1]. However, 
the impact of these comorbidities on the severity of penile curvature is still 
controversial and most studies do not examinate the serum testosterone 
levels as a risk factor for PD [8, 12]. Moreno et al. considered this last aspect, 
but did not included a control group in their investigation [9].   
 As testosterone has been shown to influence wound healing, and serum 
testosterone levels declines in the age group at risk for PD, Moreno et al. 
measured the prevalence of testosterone deficiency (TD) in PD patients and 
correlated serum concentrations of testosterone with the severity of penile 
curvature. This study identified a strong association between PD and low 
testosterone serum concentrations, as 74.4% of men with PD demonstrated 
low levels of testosterone and PD patients with low testosterone levels had a 
significantly greater degree of penile curvature than men with normal 
testosterone serum concentrations (54.3° vs. 37.1°, respectively, P=0.006) [2, 
9]. Furthermore, a recent study suggested that the presence of TD was 
associated with a significantly greater mean degree of penile curvature and a 
larger plaque size, with no difference regarding pain on erection’s complain 
[5].  
 Other study found that bioavailable testosterone (bT) and free testosterone 
(fT) were significantly lower and luteinizing hormone (LH) and sex hormone-
binding globulin (SHBG) were significantly higher in PD group than in control 
patients [13]. The plaque area was significantly larger in PD group with low 
bT/fT than in patients with normal bT/fT, not only confirming the findings of 
Moreno et al. [9], but also including a control group [13]. Moreover, this was 
the first study that assessed the androgenic levels of the populations studied, 
indicating the need for a complete hormonal assessment in PD patients and 
suggesting that further investigation is necessary to confirm the potential 
relationship between low testosterone levels and PD [13].  
 
Aims  
 
 In the present study, we aim to comprehensively evaluate the association of 
systemic comorbidities and hormonal profile with PD, and the relationship of 
hormone levels with the severity of this disease, including penile vascular 
dysfunction.   
 
Methods 
 
 We retrospectively selected 63 consecutive patients with PD and 65 controls 
followed in the Andrology consult of S. João Hospital from July 2007 until 
December 2013. 
 The diagnosis of PD was made on the basis of the presence of characteristic 
symptoms and a palpable plaque on routine examination of the penis, or an 
acquired penile curvature confirmed and characterized by an intracavernosal 
injection of 10 mcg of commercial E1 prostaglandin at the time of performing 
Penile Duplex Doppler Ultrasound (PDDU). 
 Clinical, traumatic and sexual history was gathered for patients with PD, 
including age at diagnosis, pain on erection, duration of symptoms, penile 
trauma history, type and degrees of penile curvature, and comorbidities. DM, 
hypertension, hypertriglyceridemia and hypercholesterolemia were defined as 
the report of a physician’s diagnosis of the condition or according with the use 
of medication to control the comorbidity. Smoking was evaluated by questions 
about current, past or never existed habits. The severity of penile curvature 
was classified using the Kelami system in: grade 1 – curvature 30° or less, 
grade 2 – 30° to 60°, and grade 3 – greater than 60° [5, 12]. Length and width 
of the penile plaque were determinated by physical examination.  
 PDDU measurements were carried out by a single physician, using the 
protocol suggested by the International Society for Sexual Medicine 
Standards Committee in Standard Practice in Sexual Medicine. A 12MHz 
transducer (GE Logic 7 Ultrasound System, UK) was used to record penile 
vascular flow patterns 5, 10 and 20 minutes after the injection of 10 to 20 mcg 
of commercial E1 Prostaglandin (Caverject®). Before and in-between 
evaluations, patients were left alone to prevent disturbances and consequent 
loss of sexual arousal, and asked to maintain the best possible erection by 
tactile stimulation. The mean values of Peak Systolic Velocity (mPSV), End-
Diastolic Velocity (mEDV) and Resistive Index (RI) were obtained from 
spectral waveform measurements. The classification criteria were the 
following: absence of ED for mPSV>35 cm/s, EDV<5 cm/s and RI>1; arterial 
dysfunction for mPSV≤35 cm/s; mPSV asymmetry dysfunction for an 
asymmetry in mPSV>10 cm/s; cavernous venous-occlusive dysfunction for 
mPSV≥35 cm/s and EDV≥5 cm/s; and mixed dysfunction when 35>PSV>25 
cm/s and EDV≥5 cm/s [14, 15]. 
 As a control group, we selected men who were referred to our Andrology unit 
and did not reveal evidence of PD. Men with a history of ED and/or receiving 
hormonal treatment or other treatment that might influence the variables to be 
measured were also excluded. All of them gave their informed consent for 
participating in the study and had a complete hormonal assessment available. 
 Total testosterone (TT), SHBG, estradiol, prolactin (PRL), follicle-stimulating 
hormone (FSH) and LH were determined by chemiluminescence with a 
commercially available kit (Cobas; Roche Diagnosis GmbH, Manheim, 
Germany). Levels of fT and bT were calculated using the Free and 
Bioavailable Testosterone calculator, developed at the Hormonology 
Department, University Hospital of Ghent, Belgium 
(http://www.issam.ch/freetesto.htm). The ratio estradiol/TT was also 
calculated and albumin was measured by routine laboratory methods. The 
electronic process of each patient and available digitalized records were also 
consulted.  
 In the present study, TD was defined as TT below 350  ng/dL [5]. Patients with 
PD and TD (Group 1) and those with normal TT levels (Group 2) were 
compared according to age, systemic comorbidities, TT serum concentration, 
PD’s mean duration, penile trauma history, pain on erection, length and width 
of the plaque, type and severity of curvature, curvature degrees and PDDU 
values. 
 Groups were compared with Chi-Squared test, Kruskall-Wallis test or 
Student’s t-test as appropriate, and Spearman correlation coefficients were 
computed to quantify the association between continuous variables. Statistical 
analyses were performed with Statistical Package for Social Sciences 
(SPSS®, 18.0 version). A P value of < 0.05 was considered statistical 
significant. Sample size was computed using S*Power 3.1.4 software 
considering a α of 0.05, a β of 0.20, an effect size of 0.5, and a ratio 
case/control of 1. For a two-tailed analysis, the required sample size was 64 
individuals in each group with a total sample size of 128. 
  
Main Outcome Measures 
 
 Identification of comorbidities and hormonal profile in PD patients compared 
to a control group, and correlation of characteristics of PD with hormone 
levels and PDDU values. 
 
Results  
 
 The demographic, clinical and hormonal profiles of PD patients and control 
population are shown in Table 1. The mean age was significantly different in 
both groups, being 57.4 ± 6.8 years in cases and 51.8 ± 10.2 years in controls 
(P<0.001).   
 The most commonly PD’s associated comorbidity was hypertension. This 
condition was more prevalent in PD patients than in the control group, but did 
not reach statistical significance (53.4% vs. 37.5%, P=0.113). 
 The FSH levels were significantly higher in cases than in the control group 
(5.1 mUI/ml vs. 4.2 mUI/ml, respectively; P=0.048). Serum concentrations of 
fT and bT were significantly lower in the PD group than in controls (8.0 ng/dL 
vs. 9.15 ng/dL, P=0.014, and 192.4 ng/dL vs. 221.1 ng/dL, P=0.015, 
respectively). Although TT serum concentration was also lower in cases than 
in controls, it did not reach statistical significance (457.4 ng/dL vs. 484.6 
ng/dL, respectively; P=0.392). Moreover, the estradiol/TT ratio and the mPSV 
were also lower in the PD population than in the control group, but with no 
significant difference.  
 The median of duration of symptoms was approximately 12 months. Penile 
trauma was reported by 6.7% of the patients, and 58.1% reported pain on 
erection. Penile curvature degrees’ median was 45°, with 44.3% of PD 
patients having curvature > 60° (grade 3), 39.3% between 30 and 60° and 
16.4% < 30°. The direction of primary curvature was dorsal in 63.5%, ventral 
in 4.8%, lateral in 25.4 % and with hourglass deformity in 6.3% of PD patients. 
The medians of plaque length and width were 3.0 and 2.0 cm, respectively. In 
PD group, 69.8% did not have ED. However, 12.7% had arterial dysfunction 
and 17.5% venous-occlusive dysfunction. Dupuytren’s contracture was 
present in 29% of PD patients.  
 Furthermore, the percentage of TD was higher in PD patients than in 
controls, but again with no significant difference (56.3% vs. 43.8%, P=0.475). 
Correlating characteristics of PD with the hormone profile and the PDDU 
measurements, we found that PRL levels were directly correlated with the 
degrees of curvature (r=0.375; P=0.003) and with the plaque length (r=0.391; 
P=0.002), and FSH levels were positively correlated with the plaque length 
(r=0.299; P=0.018). In addition, SHBG levels were positively correlated with 
the ratio estradiol/TT levels (r=0.396; P<0.01).  
 The degrees of penile curvature were directly correlated with the duration of 
symptoms (r=0.275; P=0.033). However, TT, bT and fT levels were not 
directly correlated with the duration of symptoms, curvature degrees and 
length/width of the plaque.  
 Moreover, there were no significant statistical associations between the 
severity of curvature with PD patients’ age, their hormone profile and PDDU 
values. 
 Comparison of PD population with TD vs. normal TT levels is presented in 
Table 2. The mean duration of PD was similar in patients in groups 1 and 2 
(10.6 vs. 12.4 months, respectively). Plaque length was significantly higher in 
group 1 than in group 2 (4.1 ± 1.6 cm vs. 3.2 ± 1.03 cm; P=0.048), whereas 
there was no significant difference in width plaque. The mean of penile 
curvature degrees was slightly greater in group 1 compared with group 2, but 
did not reach statistical significance (57.9% vs. 54.8%, P=0.583). The 
frequency of severe penile curvature was also greater in group 1 than in 
group 2 (52.9% vs. 40.9%, P=0.602). Moreover, PDDU measurements did not 
differ between groups 1 and 2.  
 
Discussion  
 
 The results of this retrospective study revealed no statistical significant 
relationship between common comorbidities and PD, apparently refuting the 
majority of contemporary evidence about this issue [1, 2, 16]. Nevertheless, 
our data are in line with the trend suggested by Rhoden et al., as we also 
found a non-significative trend towards higher prevalence of hypertension in 
PD patients [11]. We also corroborate the findings of Usta et al. that, although 
systemic comorbidities were commonly seen in PD patients, there were no 
statistical relationship between penile curvature severity and any of these 
comorbidities or PDDU values [12].  
 In our study, the percentage of TD was higher in PD patients than in controls, 
but with no significant difference, contrary to others that observed a 
significantly higher incidence of TD in PD patients than in the age-matched 
controls (76.5% vs. 41.2%, P<0.0001), suggesting a pathophysiologic role for 
TD in PD [17]. Two theories were proposed for low testosterone to be related 
with PD: (1) reduced erectile rigidity, by the important association of 
testosterone with erection and (2) impaired tissue response to injury with low 
testosterone levels [5, 9]. Adequate testosterone levels are required for 
insulin-like growth factor (IGF)-1 production and IGF-1 is a wound healing 
agent [5, 18]. Moreover, transforming growth factor (TGF)-β1 is 
overexpressed in PD. TGF-β1 stimulates collagen synthesis and induces 
other profibrotic factors’ production [5, 9, 19]. Evidence demonstrated that 
testosterone was involved in the downregulation of TGF-β1 production [5]. 
Therefore, testosterone is a necessary androgen to maintain the wound 
healing response. A TD results in catabolism and impaired healing [5, 18]. 
Reduced rigidity might lead to greater penile bending, thus predisposing the 
penis to microtrauma and PD [5, 20].  
 The main impetus of the present study was to determinate if the hormone 
profile was associated with PD and with the severity of PD. These potential 
relationships received only minor investigation to date, with only one study 
reporting results about both outcomes [13]. Our study corroborated their 
findings in terms of fT and bT levels, which were significantly lower in the PD 
patients’ group than in controls, and plaque length, that was significantly 
higher in PD patients with TD. However, we did not find significant correlation 
of TD with symptoms’ duration and curvature degrees.  
 Serum concentrations of fT and bT are generally considered more reflective 
of androgen status than TT values, as they are not confounded by SHBG 
levels. Therefore, studies using these two parameters might be more relevant 
to evaluate if low testosterone plays a potential role in the development of PD 
[9, 13]. 
 A significant correlation between the ratio estradiol/TT with the severity of 
penile curvature (r=0.476, P=0.0001) was observed by Moreno et al., 
although no explanation was suggested for how or why estradiol may 
contribute to PD [9]. As the aging process continues uncontested and 
testosterone levels decrease with age, there is a relative accumulation of fatty 
tissue and aromatization accelerates the conversion of testosterone to 
estradiol. This additional secondary estradiol inhibition results in the 
maintenance of a TD state [21, 22]. Despite of the fact that we did not find a 
statistical significant correlation, further investigation about this item may be 
an important step for improving our understanding of PD.  
 This was the first study reporting positive correlations between other 
hormone levels than testosterone with the severity of the PD. Serum 
concentrations of PRL were directly correlated with the degrees of curvature 
and with the plaque length, as well as FSH levels were positively correlated 
with the plaque length. It remains unknown how and why PRL and FSH levels 
contribute to PD. Evidence suggests that TD is associated with the severity of 
PD and that severe hyperprolactinemia inhibits testosterone secretion [9, 23]. 
However, despite of PRL levels being higher in PD patients than in controls, 
they were in the normal range. Nevertheless, a TD continuous state can 
explain not only the stimulation of FSH production, but also its influence on 
the severity of the disease.  
 Moreover, we were the first to investigate if TD was associated with PDDU 
measurements in PD patients. These values were similar in groups 1 and 2, 
but as evidence reports a strong association between TD and ED in aging 
men [24] and ED is present in a high percentage of men with PD, varying from 
20 to 54% [11, 25], this association may deserve further studies.   
 There were some limitations in our study, one being its retrospective design. 
Because of small sample size, the statistical power of the analysis was 
limited. A 31-year age spread in a relatively small sample size of PD patients 
might have interfered with data analysis. Thus, studies using larger samples 
are still required to elucidate the true association between hormone levels and 
PD characteristics.   
 
Conclusion 
 
 Our investigation suggested a possible relationship between hormone levels 
and PD, beyond TD. Furthermore, low levels of fT and bT were the biggest 
contribution to TD in PD patients. Although these parameters were not 
correlated with severity of PD, they were significantly lower in PD patients, 
corroborating the potential role of low testosterone in the pathophysiology of 
this disease. 
 Therefore, further studies, namely prospective trials with a complete 
hormonal assessment in PD patients, are needed to confirm or refute this 
evidence.  
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Tables 
Table 1   Demographic, clinical and hormonal profiles of PD patients and control population 
 PD patients  Controls P value* 
Number of subjects  63 65  
Age (years) 57.4 ± 6.8 51.8 ± 10.2 < 0.001 
Hypertension 31 (53.4%) 24 (37.5%) 0.113 
Diabetes mellitus 19 (35.2%) 24 (37.5%) 0.946 
Hypercholesterolemia  20 (36.4%) 32 (54.2%) 0.084 
Hypertriglyceridemia 13 (24.5%) 20 (33.9%) 0.380 
Smoking   < 0.001 
 - Never smoking  51 (82.3%) 25 (39.1%)  
 - Current smoking 9 (14.5%) 17 (26.6%)  
 - Past smoking 2 (3.2%) 22 (34.4%)  
Sex hormone-binding globulin (nmol/L) 36.8 (30.1-52.7) 35.8 (26.8-49.8) 0.312 
Albumin (g/L) 44.1 ± 2.5 44.3 ± 2.9 0.600 
Follicle-stimulating hormone (mIU/mL) 5.1 (4.0-7.8) 4.2 (3.3-6.2) 0.048 
Luteinizing hormone (mIU/mL) 4.3 (3.3-5.9) 4.2 (2.9-5.6) 0.340 
Total testosterone (ng/dL) 457.4 ± 172.6 484.6 ± 185.3 0.392 
Free testosterone (ng/dL) 8.0 ± 2.3 9.15 ± 2.7 0.014 
Bioavailable testosterone (ng/dL) 192.4 ± 56.8 221.1 ± 69.9 0.015 
Prolactin (ng/ml) 7.9 ± 6.8 7.6 ± 3.4 0.800 
Estradiol (pg/ml)  27.5 ± 13.3 32.2 ± 18.2 0.110 
Estradiol (pg/ml)/total testosterone (ng/dL) 0.063 ± 0.032 0.077 ± 0.058 0.110 
mPSV (cm/s) 49.3 ± 19.6 53.5 ± 14.5 0.235 
mEDV (cm/s) 0.0 (0.0-5.1) 0.0 (0.0-3.8) 0.168 
RI 1.0 (0.9-1) 1.0 (1.0-1.0) 0.054 
 
Data are presented as the mean ± standard deviation, median (percentile 25-percentile 75) or number of 
subjects in each group with percentages in parentheses, as appropriate. PD = Peyronie’s disease; mPSV = 
mean values of Peak Systolic Velocity; mEDV = mean values of End-Diastolic Velocity; RI = Resistive Index. 
*Significance level at P < 0.05.  	  	  	  	  
 
 
 
 
 
 
 
Table 2   Distribution of Peyronie’s disease (PD) according to total testosterone (TT) levels 
 Group 1  Group 2 P value*  
Number of subjects 18 45 0.475 
Age (years) 56.1 ± 6.9 57.9 ± 6.8 0.345 
Smoking (%)   0.262 
 - Never smoking  94.4 77.3  
 - Current smoking 5.6 18.2  
 - Past smoking 0.0 4.5  
Hypercholesterolemia (%) 43.8 33.3 0.674 
Hypertriglyceridemia (%) 26.7 23.7 0.822 
Hypertension (%) 37.5 59.5 0.227 
Diabetes mellitus (%) 43.8 31.6 0.587 
Dupuytren’s contracture (%) 11.1 36.4 0.093 
Total testosterone (ng/dL) 300.1 ± 46.5 520.3 ± 164.2 <0.001 
Duration of PD (months) 10.6 ± 4.8  12.4 ± 10.4 0.481 
History of penile trauma (%) 12.5 4.5 0.287 
Pain on erection (%) 58.8 57.8 0.941 
Plaque length (cm) 4.1 ± 1.6 3.2 ± 1.03 0.048 
Plaque width (cm) 1.8 ± 0.6 1.9 ± 0.7 0.431 
Curvature type (%)   0.987 
- dorsal 61.1 64.4  
- ventral 5.6 4.4  
- lateral 27.8 24.4  
- hourglass deformity 5.6 6.7  
Curvature degrees 57.9 ± 20.2 54.8 ± 20.1 0.583 
Curvature severity (%)   0.602 
 - < 30° (grade 1) 17.6 15.9  
- 30-60° (grade 2) 29.4 43.2  
- > 60° (grade 3) 52.9 40.9  
Erectile dysfunction diagnosis (%)   0.394 
- absence of erectile dysfunction 61.1 73.3  
- arterial dysfunction 11.1 13.3  
- venous-occlusive dysfunction 27.8 13.3  
 
Data are presented as the mean ± standard deviation or percentage, as appropriate, for a total of 18 PD 
patients with TD (Group 1) and 45 patients with normal TT levels (Group 2). mPSV = mean values of 
Peak Systolic Velocity; mEDV = mean values of End-Diastolic Velocity; RI = Resistive 
Index.*Significance level at P < 0.05.  	  	  
 
 
 
 
 	  
mPSV (cm/s) 50.00 ± 24.2 48.99 ± 17.6 0.870 
mEDV (cm/s) 3.56 ± 5.3 3.22 ± 4.3 0.813 
RI 0.93 0.95 0.451 
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